1D·

Bayer shares shoot up 9% - these are the reasons!

$BAYN (+1.34%)

Bayer has made progress in a clinical trial with Asundexian, a drug for the treatment of strokes. Asundexian has blockbuster potential and catapulted the share price up more than 9% on Monday.


Summarized for you

Bayer makes progress with Asundexian, shares up 9%.

Drug lowers stroke risk, FDA fast-track.

Market potential of Asundexian at 3 billion euros.

Report: The year-end rally rolls on


https://www.wallstreet-online.de/nachricht/20200506-milliardenmarkt-sicht-bayer-aktie-schiesst-9-plus-gruende

previw image
17
12 Comments

profile image
Cool now only minus 70%
35
profile image
@Smudeo but +55% over the year ;) it's all a question of the investment period
2
profile image
@Shareholder You said buy and hold, but that wasn't right again 🤑
2
profile image
Dude another one of my rookie mistakes, was about to top up at €19🤬
1
profile image
2
profile image
@Smudeo I thought I was the only remaining shareholder in the company.
3
profile image
@Smudeo I already have, shit😂
1
@Yasin21 me too😅😅
1
profile image
Thought I wasn't seeing right this morning. According to my experience and my little hand, the number at Bayer should be red. But the fact is. Green😲
How do you see Bayer - hands off because of casa Monsanto or potential for rebound?
profile image
@Shareholder
I am cautious about making a forecast for bayer
profile image
Great - I'm only 54% behind. First purchase was in 2008 and is in the tax-free portfolio. Together with Mercedes and BASF.
profile image
@gloinvest
Mercedes I am also still slightly in the red.
But the dividend is a consolation.
Bayer and BASF have never been my cup of tea.
I'm positioned differently in the pharmaceutical sector, where I also like to focus on niches. Because they always have takeover potential.
Join the conversation